FAQ

Direct Thrombin Inhibitor [EPC]

Known as: Direct Thrombin Inhibitor 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
02420022016

Related topics

Related topics

1 relation
Direct thrombin inhibitors

Related mentions per year

Related mentions per year

2000-2017
20002005201020152020
Direct Thrombin Inhibitor [EPC]
Direct thrombin inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Novel oral anticoagulants for heparin-induced thrombocytopenia
To review the use of the novel oral anticoagulant (NOAC) agents for the treatment of heparin-induced thrombocytopenia (HIT) from… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
The immobilization of a direct thrombin inhibitor to a polyurethane as a nonthrombogenic surface coating for extracorporeal circulation.
A biomaterial with both antithrombin and antiplatelet properties is the ideal surface for use in extracorporeal circulation (ECC… (More)
Is this relevant?
2015
2015
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
INTRODUCTION The blood coagulation cascade consists of two pathways, the tissue factor (TF)-dependent extrinsic pathway and the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses: a prospective study based on peak and trough plasma levels.
OBJECTIVES To study dabigatran etexilate, a new oral anticoagulant that functions as a direct thrombin inhibitor. METHODS This… (More)
Is this relevant?
2012
2012
Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
This study evaluated the potential impact of concomitant digoxin on the pharmacokinetics and pharmacodynamics of dabigatran… (More)
Is this relevant?
2011
2011
Impact of a Pharmacist-Directed Anticoagulation Service on the Quality and Safety of Heparin-Induced Thrombocytopenia Management.
BACKGROUND The use of anticoagulant medications is complex and prone to error in the inpatient setting. Patients with heparin… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion.
BACKGROUND The diagnosis of heparin-induced thrombocytopenia (HIT) is challenging. Over-diagnosis and over-treatment are common… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 3
Is this relevant?
2010
2010
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
AZD0837, currently in clinical development, is a once-daily oral anticoagulant that is bioconverted to AR-H067637, a selective… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2007
2007
Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin.
The leech-derived protein hirudin is the most potent naturally occurring direct thrombin inhibitor (DTI) known and is used… (More)
  • figure 1
  • table 1
Is this relevant?
2003
2003
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
OBJECTIVES The effects of ximelagatran, an oral direct thrombin inhibitor (DTI), recombinant hirudin (r-hirudin) and enoxaparin… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?